Literature DB >> 30617114

Original Antigenic Sin: How First Exposure Shapes Lifelong Anti-Influenza Virus Immune Responses.

Ali Zhang1, Hannah D Stacey1, Caitlin E Mullarkey1, Matthew S Miller2.   

Abstract

The term "original antigenic sin" (OAS) was first used in the 1960s to describe how one's first exposure to influenza virus shapes the outcome of subsequent exposures to antigenically related strains. In the decades that have passed, OAS-like responses have been shown to play an integral role in both protection from and susceptibility to infections. OAS may also have an important deterministic role in the differential efficacy of influenza vaccine responses observed for various age cohorts across seasons. In this article, we review how the understanding of OAS has progressed from its initial description and highlight important outstanding questions in need of further study.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30617114     DOI: 10.4049/jimmunol.1801149

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Authors:  Weina Sun; Ericka Kirkpatrick; Megan Ermler; Raffael Nachbagauer; Felix Broecker; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

2.  Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination.

Authors:  Carolyn M Boudreau; Wen-Han Yu; Todd J Suscovich; H Keipp Talbot; Kathryn M Edwards; Galit Alter
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

3.  Preexisting subtype immunodominance shapes memory B cell recall response to influenza vaccination.

Authors:  Rodrigo B Abreu; Greg A Kirchenbaum; Emily F Clutter; Giuseppe A Sautto; Ted M Ross
Journal:  JCI Insight       Date:  2020-01-16

Review 4.  Host Factors Impact Vaccine Efficacy: Implications for Seasonal and Universal Influenza Vaccine Programs.

Authors:  Santosh Dhakal; Sabra L Klein
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

5.  Original Antigenic Sin: Friend or Foe in Developing a Broadly Cross-Reactive Vaccine to Influenza?

Authors:  Priyadharshini Devarajan; Susan L Swain
Journal:  Cell Host Microbe       Date:  2019-03-13       Impact factor: 21.023

6.  A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas.

Authors:  Brittani N Blunck; Letisha Aideyan; Xunyan Ye; Vasanthi Avadhanula; Laura Ferlic-Stark; Lynn Zechiedrich; Brian E Gilbert; Pedro A Piedra
Journal:  Vaccine       Date:  2021-01-26       Impact factor: 3.641

7.  COVID-19 is not "just another flu": a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria.

Authors:  Pawelka Erich; Karolyi Mario; Mader Theresa; Omid Sara; Kelani Hasan; Baumgartner Sebastian; Ely Sarah; Hoepler Wolfgang; Jilma Bernd; Koenig Franz; Laferl Hermann; Traugott Marianna; Turner Michael; Seitz Tamara; Wenisch Christoph; Zoufaly Alexander
Journal:  Infection       Date:  2021-05-13       Impact factor: 3.553

Review 8.  Influenza immune escape under heterogeneous host immune histories.

Authors:  Rachel J Oidtman; Philip Arevalo; Qifang Bi; Lauren McGough; Christopher Joel Russo; Diana Vera Cruz; Marcos Costa Vieira; Katelyn M Gostic
Journal:  Trends Microbiol       Date:  2021-07-01       Impact factor: 17.079

Review 9.  Intra-species sialic acid polymorphism in humans: a common niche for influenza and coronavirus pandemics?

Authors:  Xi Jiang; Ming Tan; Ming Xia; Pengwei Huang; Michael A Kennedy
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

10.  Is 'original antigenic sin' complicating indian vaccination drive against Covid-19?

Authors:  Vipin M Vashishtha
Journal:  Hum Vaccin Immunother       Date:  2021-06-29       Impact factor: 4.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.